The clinical-stage biotech didn't have any revenue in the first quarter. But it made progress in several key areas.
News & Analysis: Achillion Pharmaceuticals
Reaching a key clinical study milestone provided a nice boost to the biotech stock.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
The aftermath from its disappointing pipeline update early in the week continued to hurt the biotech stock.
Reverberations from the biotech's pipeline update on Monday continued to weigh on the stock.
Some stocks missed out on the day's minor rally.
Achillion's interim data peek failed to impress investors.
Worries about an imminent clinical update sent the stock lower.
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
Achillion got an important nod from European regulators today for its lead product candidate.